Pain Bust R Ii

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the temporary relief of minor pain associated with arthritis.

There are no teratogenic or nonteratogenic effects associated with this medication.

Dosage and Administration

For adults and children over 17 years of age, the recommended dosage is to apply the product generously to the affected area. The application should be followed by a gentle massage into the painful area until the product is thoroughly absorbed into the skin. This process may be repeated as necessary, but should not exceed four applications within a 24-hour period.

For children 17 years of age or younger, the use of this product is not advised without prior consultation with a healthcare professional.

Contraindications

Use of this product is contraindicated in the following situations:

Tight bandaging or the application of a heating pad is not recommended, as it may exacerbate adverse effects. Contact with eyes or mucous membranes should be strictly avoided to prevent irritation or injury. Additionally, application to wounds or damaged skin is contraindicated due to the potential for increased sensitivity or adverse reactions.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid use in individuals with a known allergy to salicylates, including aspirin, unless specifically directed by a physician.

Patients should be instructed to discontinue use and consult a healthcare provider if any of the following occur: the condition worsens, symptoms persist for more than 7 days, symptoms resolve and then recur within a few days, redness appears, or irritation develops.

In the event of accidental ingestion, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Side Effects

Patients should be aware of the potential for adverse reactions associated with the use of this medication. A significant warning includes an allergy alert; individuals should not use this product if they are allergic to salicylates, including aspirin, unless directed by a healthcare professional.

In clinical practice, patients are advised to stop using the medication and consult a doctor if their condition worsens, if symptoms persist for more than 7 days, or if symptoms clear up and then recur within a few days. Additionally, the presence of redness or the development of irritation are also indicators that medical advice should be sought. These precautions are essential to ensure patient safety and to mitigate the risk of serious adverse reactions.

Drug Interactions

Patients should be advised against the use of this medication if they have a known allergy to salicylates, including aspirin, unless specifically directed by a healthcare professional.

No specific drug or laboratory test interactions have been identified in the available data. Therefore, routine monitoring or dosage adjustments related to drug interactions are not necessary.

Packaging & NDC

Below are the non-prescription pack sizes of Pain Bust R Ii (menthol, methyl salicylate). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 17 years or younger should not use this medication without consulting a healthcare professional. It is essential for caregivers to seek medical advice prior to administration to ensure safety and appropriateness of treatment for this age group.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of accidental ingestion, it is imperative to seek immediate medical assistance or contact a Poison Control Center. Prompt action is crucial to mitigate potential risks associated with overdosage.

Healthcare professionals should be aware that symptoms of overdosage may vary depending on the substance involved. Therefore, a thorough assessment of the patient's condition is essential.

Management of overdosage typically involves supportive care and symptomatic treatment. Continuous monitoring of the patient's vital signs and clinical status is recommended. In cases where specific antidotes are available, their administration should be considered based on the clinical scenario.

It is essential for healthcare providers to remain vigilant and prepared to implement appropriate interventions in the event of an overdosage situation.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Reports of issues associated with this product have been received through voluntary reporting and surveillance programs. Individuals are encouraged to report any adverse events or concerns to the designated telephone number or address provided on the product packaging.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center in the event of accidental ingestion of the product.

Patients should be instructed to discontinue use and consult a doctor if any of the following occur: the condition worsens, symptoms persist for more than 7 days, symptoms resolve and then recur within a few days, or if redness or irritation develops.

When using this product, it is essential for patients to follow the directions provided. They should be cautioned against bandaging the area tightly or using a heating pad in conjunction with the product. Additionally, patients must be reminded to avoid contact with the eyes and mucous membranes, and to refrain from applying the product to wounds or damaged skin.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a cool place to maintain its integrity and efficacy. Proper storage conditions are crucial for ensuring the product remains effective throughout its shelf life.

Additional Clinical Information

Patients should be advised that the product is for external use only. Clinicians should inform patients of the following precautions: do not use if allergic to salicylates (including aspirin) unless directed by a doctor. When applying the product, it should be used as directed, avoiding tight bandaging or heating pads, and contact with eyes or mucous membranes. It should not be applied to wounds or damaged skin. Patients should discontinue use and consult a doctor if the condition worsens, symptoms persist for more than 7 days, or if redness or irritation develops.

For administration, the product is applied topically. Adults and children over 17 years should apply generously to the affected area and massage until thoroughly absorbed, with a maximum frequency of four times daily. Children 17 years or younger should not use the product without consulting a doctor. Additionally, if a patient is pregnant or breastfeeding, they should seek advice from a health professional before use. The product should be kept out of reach of children, and in the event of accidental ingestion, medical help or contact with a Poison Control Center should be sought immediately.

Drug Information (PDF)

This file contains official product information for Pain Bust R Ii, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)